Desenvolvimento de dosimetria por voxel aplicável à terapia com radionuclídeos


  1. Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005; 46 Suppl 1:28S-37S.
  2. Sabet A, Biersack HJ, Ezziddin S. Advances in peptide receptor radionuclide therapy. Semin Nucl Med 2016; 46:40-6.
  3. Parker C, Nilsson S, Heinrich D, Helle SI, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213-23.
  4. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-63.
  5. Dorn R, Kopp J, Vogt H, Heidenreich P, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003; 44:451-6.
  6. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46:1023-27.
  7. Dewaraja YK, Frey EC, Sgouros G, Brill AB, et al. MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012; 53:1310-25.
  8. Kost SD, Dewaraja YK, Abramson RG, Stabin MG. VIDA: a voxel-based dosimetry method for targeted radionuclide therapy using Geant4. Cancer Biother Radiopharm 2015; 30:16-26.
  9. Dieudonné A, Hobbs RF, Lebtahi R, Maurel F, et al. Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods. J Nucl Med 2013; 54:236-43.
  10. Walker RC, Smith GT, Liu E, Moore B, et al. Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med 2013; 54:855-60.
  11. Gupta SK, Singla S, Thakral P, Bal C. Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE. Clin Nucl Med 2013; 38:188-94.
  12. Pauwels S, Barone R, Walrand S, Borson-Chazot F, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 2005; 46 Suppl 1:92S-8S.
  13. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962; 87:171-82.
  14. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, et al. Patient- specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004; 45:1366-72.
  15. Medvedec M. Thyroid stunning, J Nucl Med 2001; 42:1129-31.
  16. Willegaignon J, Sapienza MT, Buchpiguel CA. Comparison of different dosimetric methods for red marrow absorbed dose calculation in thyroid cancer therapy. Radiat Prot Dosimetry 2012; 149:138-46.